Endocrine Abstracts

Introduction: Osteoporosis is a disease characterized by a low bone mass and the development of nontraumatic fractures, most commonly in the spine. However, bone mineral density (BMD) alone is not completely satisfactory in vertebral fracture risk assessment.Aim of the study: To identify clinical and laboratoristic factors associated with an increased risk of vertebral fractures in osteoporotic Caucasian women and to define a new clinically relevant scal...

Anabolic therapies represent a major advance in the management of severe osteoporosis. Parathyroid hormone (PTH) and human recombinant PTH peptide 1–34 (Teriparatide) demonstrated an increase in bone mineral density and a significant reduction in vertebral fractures in patients with osteoporosis when given for 18–24 months. The intermittent administration of PTH or teriparatide stimulates osteoblastic function, improves bone architecture and has an additional analges...